Metadata record for the article: Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition

Summary

This
metadata record provides details of the data supporting the claims of the
related article: “Synergistic targeting of BRCA1
mutated breast cancers with PARP and CDK2 inhibition”.

The
related study tested the hypothesis that for basal-like breast cancers (BLBC) two
markers--cyclin E1 and BRCA1 loss--are mutually exclusive and define
therapeutic subsets.

Type of data:
clinical data; flow cytometry; immunohistochemistry (IHC); Dual-color In Situ
Hybridization (ISH); survival analysis

Subject of
data: antibodies; Eukaryotic cell lines; Mus
musculus (NOD-SCID-IL2γR-/- (NSG)); Homo
sapiens

Population
characteristics: 308 breast cancer samples were used from The Kathleen
Cuningham Foundation Consortium for research into Familial Breast cancer (kConFab;
http://www.kconfab.org) cohort. The selection of the population and recruitment
are described in https://doi.org/10.1186/bcr1377.

Data
access

Where
possible (and not including sensitive/patient-identifying data), the data underlying the
claims of the related article have been made openly available in .xlsx spreadsheet
format as part of this data record.

The patient
dataset is not publicly available in order to protect patient confidentiality. The
clinical cohort was collected and managed by kConFab, who will consider
applications to access the cohort via www.kConFab.org.
Processed patient data (Excel & Prism formats) can be accessed upon
reasonable enquiry with the corresponding author.

Cell lines and vectors engineered by the authors for this study are available upon reasonable request to the corresponding author. PDX models were provided by Dr Alex Swarbrick (HCI-002), E.L. (PDX 11-26) and V.S.(PDX124).

Corresponding author(s) for this study

C.
E. Caldon, 384 Victoria St, Darlinghurst, 2010 Australia. Phone: + 612 9355 5878
Fax: [phone] Email: [e-mail]

Study approval

Ethics
oversight is described in https://doi.org/10.1186/bcr1377
and at www.kConfab.org. Ethics board
approval was obtained for patients’ recruitment, sample collection and research
studies. Written informed consent was obtained from all participants. All in vivo experiments, procedures and
endpoints were approved by the Garvan Institute of Medical Research Animal
Ethics Committee (protocol 18/26) or the VHIO Animal Ethics Committee (protocol
17/42).